Safety Concerns Surrounding Venetoclax in Multiple Myeloma Trials

This chapter discusses the latest issues surrounding venetoclax in multiple myeloma treatment, focusing on the FDA's enrollment hold due to safety concerns. It emphasizes the study's findings related to death rates and infections, raising critical questions about the drug's efficacy and safety profile in clinical trials.